Pharmaceutical Continuous Manufacturing Market Analysis 2031
The pharmaceutical continuous manufacturing market size is projected to reach US$ 4.67 billion by 2031 from US$ 2.08 billion in 2023. The market is expected to register a CAGR of 10.6% during 2023–2031. Growing support from regulatory bodies, rising adoption by contract and in-house manufacturers for drug manufacturing procedures, and advantages associated with continuous manufacturing are likely to remain key trends in the market.
Pharmaceutical Continuous Manufacturing Market Analysis
Pharmaceutical companies are constantly investing into innovative manufacturing technologies for gaining competitive advantage and staying ahead in the market, thereby driving the continuous manufacturing market. Continuous manufacturing permits the pharmaceutical companies to have greater control over their production process, which helps in quality improvement and consistency of the end product, thereby reducing deviations, wastage, and saving rework time and recall costs. Pharmaceutical continuous manufacturing can improve the quality of the final product, enhance process control, and permit real-time release testing. The European Medicines Agency (EMA) and the US Food and Drug Administration (FDA) are the regulatory bodies that are increasingly favouring the use of continuous manufacturing in the pharmaceutical industry. Furthermore, continuous manufacturing has become more appealing and practical in the pharmaceutical industry because of the improved process monitoring, control, and optimization provided through the means of automation, system control, data analytics, and process analysis technology (PAT), which drives the market.
Pharmaceutical Continuous Manufacturing Market Overview
As a viable solution for minimizing pressure and reducing drug development time and costs, while also maintaining end-product quality and supply in the pharmaceutical industry continuous manufacturing is highly being used. Therefore, owing to such benefits the continuous manufacturing market is witnessing healthy growth. Additionally, growing initiatives for promoting the use of continuous pharmaceutical manufacturing systems by the Food and Drug Administration (FDA) and the numerous advantages of continuous manufacturing systems over batch manufacturing are some of the main factors that are driving the growth of the market. However, on the other hand the high cost implementation of pharmaceutical continuous manufacturing systems is likely to hinder the market growth.
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Pharmaceutical Continuous Manufacturing Market: Strategic Insights
Market Size Value in US$ 1,459.53 Million in 2019 Market Size Value by US$ 3,064.38 Million by 2027 Growth rate CAGR of 9.8% from 2020-2027 Forecast Period 2020-2027 Base Year 2020
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Customize Research To Suit Your Requirement
We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.
Pharmaceutical Continuous Manufacturing Market: Strategic Insights
| Market Size Value in | US$ 1,459.53 Million in 2019 |
| Market Size Value by | US$ 3,064.38 Million by 2027 |
| Growth rate | CAGR of 9.8% from 2020-2027 |
| Forecast Period | 2020-2027 |
| Base Year | 2020 |
Mrinal
Have a question?
Mrinal will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.
Speak to Analyst
Pharmaceutical Continuous Manufacturing Market Drivers and Opportunities
Advantages Offered by Continuous Manufacturing Process to Favor Market
Pharmaceutical continuous manufacturing are being embraced and gaining importance due to the rising demand for biologics and flexible manufacturing alternatives. The companies that are transitioning to continuous manufacturing procedures are getting approvals from the FDA quickly. The the continuous manufacturing process offers many advantages that include time-efficiency, reduced energy needs and wastage, and increased productivity. In addition, the process reduces the risk of human error owing to the involvement of few of people in the manufacturing process. Therefore, owing to aforementioned advantages offered by continuous manufacturing the market is expected to grow over the coming years.
Emerging Markets to Provide High Potential Growth Opportunities
Attractive outsourcing locations for biopharmaceutical industries are emerging in the regions such as Asia Pacific and South & Central. China and India provide low manufacturing and operating costs that are significant factors for driving the market growth in the Asia Pacific region. Both China and India indicate positive future outlook for the market owing to the recent growth in the biopharmaceutical industry in both countries. In January 2020, STA Pharmaceutical Co., Ltd., – a subsidiary of WuXi AppTec opened a new large-scale oligonucleotide active pharmaceutical ingredient (API) manufacturing facility in China. Thus, the emerging markets suitable for biopharmaceutical industry are likely to act as high potential growth and revenue generators in the pharmaceutical continuous manufacturing market.
Pharmaceutical Continuous Manufacturing Market Report Segmentation Analysis
Key segments that contributed to the derivation of the pharmaceutical continuous manufacturing market analysis are product, application, and end user.
- Based on product, the pharmaceutical continuous manufacturing market is segmented into integrated systems, semi-continuous systems, and controls. The integrated systems segment held the largest market share in 2023 and the same is expected to register highest CAGR during the forecast period.
- By application, the market is divided end product manufacturing and API manufacturing. The end product manufacturing segment is further divided into solid dosage manufacturing and liquid dosage manufacturing. The end product manufacturing segment held the largest share of the market in 2023. However, the API manufacturing segment is anticipated to register highest CAGR during 2021–2031.
- Based on end user, the pharmaceutical continuous manufacturing market is bifurcated into full-scale manufacturing companies and R&D departments. The full-scale manufacturing segment held the largest market share in 2023 and the same is expected to register highest CAGR during the forecast period.
Pharmaceutical Continuous Manufacturing Market Share Analysis by Geography
The geographic scope of the Pharmaceutical Continuous Manufacturing market report is mainly divided into five regions: North America, Asia Pacific, Europe, Middle East & Africa, and South & Central America.
North America has dominated the pharmaceutical continuous manufacturing market. The factors leading to the growth of the pharmaceutical continuous manufacturing market in North America are owing to the growing support from FDA for promoting the use of continuous manufacturing over batch manufacturing, increasing shortage of drugs in the region and presence of pharmaceutical giants that can afford the large initial investments to set up continuous manufacturing processes. Majority of the industries in the US embraced continuous manufacturing processes since decades. The US holds a dominating position within North America due to factors such as increasing number of pharmaceutical players adopting continuous manufacturing procedures, advancements in the field of manufacturing technologies and efficiency offered by these set-ups to scale up the production volumes. In addition, various initiatives were undertaken by the US FDA for promoting continuous manufacturing in the US within the pharmaceutical industries.
Pharmaceutical Continuous Manufacturing Market Report Scope
Pharmaceutical Continuous Manufacturing Market News and Recent Developments
The Pharmaceutical Continuous Manufacturing market is evaluated by gathering qualitative and quantitative data post primary and secondary research, which includes important corporate publications, association data, and databases. A few of the developments in the Pharmaceutical Continuous Manufacturing market are listed below:
- South Korea-based contract development and manufacturing organization (CDMO) SK Bioscience has broken ground on an approximately 4,200 m2 expansion of its L House vaccine manufacturing facility in Andong, Gyeongsangbuk-do, South Korea, which will serve as the production base for pneumococcal conjugate vaccine candidate GBP410, jointly developed by SK Bioscience and Sanofi, who are co-investing in the expansion. (SK Bioscience, Press Release, March 2024)
- Phlow Corp., a US-based essential medicines public benefit company, announced strategic alliances with both Virginia Commonwealth University’s (VCU) Medicines for All Institute and AMPAC Fine Chemicals to provide contract continuous manufacturing research and development (R&D) services for small molecule pharmaceutical products. In addition to its robust and growing internal capabilities, Phlow’s network of established, innovative, and experienced strategic partners will provide high quality, US-based advanced manufacturing solutions for small molecule active pharmaceutical ingredients (APIs) and registered starting materials (RSMs) across all stages of development using state-of-the-art technologies and unique industry insights. (Phlow Corp., News, March 2022)
Pharmaceutical Continuous Manufacturing Market Report Coverage and Deliverables
The “Pharmaceutical Continuous Manufacturing Market Size and Forecast (2021–2031)” report provides a detailed analysis of the market covering below areas:
- Pharmaceutical continuous manufacturing market size and forecast at global, regional, and country levels for all the key market segments covered under the scope
- Pharmaceutical continuous manufacturing market trends as well as market dynamics such as drivers, restraints, and key opportunities
- Detailed PEST and SWOT analysis
- Pharmaceutical continuous manufacturing market analysis covering key market trends, global and regional framework, major players, regulations, and recent market developments
- Industry landscape and competition analysis covering market concentration, heat map analysis, prominent players, and recent developments for the pharmaceutical continuous manufacturing market
- Detailed company profiles
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
Product ; Application ; End User and Geography
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
Argentina, Australia, Brazil, Canada, China, France, Germany, India, Italy, Japan, Mexico, Saudi Arabia, South Africa, South Korea, Spain, United Arab Emirates, United Kingdom, United States
Frequently Asked Questions
The North America region dominated the pharmaceutical continuous manufacturing market in 2023.
Increasing shortage of medicines, and advantages offered by continuous manufacturing process are the driving factors impacting the pharmaceutical continuous manufacturing market.
Growing support from regulatory bodies, rising adoption by contract and in-house manufacturers for drug manufacturing procedures, and advantages associated with continuous manufacturing are likely to act as future trends for the pharmaceutical continuous manufacturing market.
GEA Group and Thermo Fisher Scientific Inc. are the leading players operating in the pharmaceutical continuous manufacturing market.
US$ 4.67 billion would be the estimated value of the pharmaceutical continuous manufacturing market by 2031.
10.6% is the CAGR of the pharmaceutical continuous manufacturing market.
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published many reports and advised several clients across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organizations are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in the last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/Sales Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- 3.1 Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- 3.2 Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- 3.3 Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- 3.4 Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Get Free Sample For